bluuebunny/crossref_metadata_2025_split huggingface dataset:
Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data
Authors: Bordeleau Louise , Szalai John Paul , Ennis Marguerite , Leszcz Molyn , Speca Michael , Sela Rami , Doll Richard , Chochinov Harvey M. , Navarro Margaret , Arnold Andrew , Pritchard Kathleen I. , Bezjak Andrea , Llewellyn-Thomas Hilary A. , Sawka Carol A. , Goodwin Pamela J. 
Published: May 2003

Purpose: To evaluate the effect of a standardized group psychosocial intervention on health-related quality of life (HrQOL) in women with metastatic breast cancer and to explore the effect of missing data in HrQOL analyses. Patients and Methods: Between 1993 and 1998, seven Canadian centers randomly assigned 235 eligible women to participate in a weekly, 90-minute, therapist-led support group that adhered to principles of supportive-expressive (SE) therapy or to a control arm (no SE). All women received educational material and any type of medical or psychosocial care deemed necessary. HrQOL data were prospectively collected using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) at baseline, 4, 8, and 12 months. The primary HrQOL analyses compared scores in the two study arms. Analyses were limited to women with appropriate baseline HrQOL information (n = 215). Results: Baseline EORTC QLQ-C30 scores were not different between the two study arms (all P > .05). Primary analysis of all subscales failed to show a significant influence of the intervention on HrQOL (all P > .05). There was a significant deterioration over time in several functional scales of the EORTC QLQ-C30: global (P = .03), physical (P = .0002), role (P = .01), and cognitive functioning (P = .04); and in symptom scales: dyspnea (P = .007), appetite loss (P = .04), and fatigue (P = .003); these changes were independent of randomization allocation. Results were similar in additional analyses of overall HrQOL using a variety of approaches to handling missing data. Conclusion: Supportive-expressive group therapy in patients with metastatic breast cancer does not appear to influence HrQOL, as measured by the EORTC QLQ-C30.
Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413
Authors: Roach M. , DeSilvio M. , Lawton C. , Uhl V. , Machtay M. , Seider M.J. , Rotman M. , Jones C. , Asbell S.O. , Valicenti R.K. , Han S. , Thomas C.R. , Shipley W.S. 
Published: May 2003

Purpose: This trial tested the hypothesis that combined androgen suppression (CAS) and whole-pelvic (WP) radiotherapy (RT) followed by a boost to the prostate improves progression-free survival (PFS) by 10% compared with CAS and prostate-only (PO) RT. This trial also tested the hypothesis that neoadjuvant and concurrent hormonal therapy (NCHT) improves PFS compared with adjuvant hormonal therapy (AHT) by 10%. Materials and Methods: Eligibility included localized prostate cancer with an elevated prostate-specific antigen (PSA) ≤ 100 ng/mL and an estimated risk of lymph node (LN) involvement of 15%. Between April 1, 1995, and June 1, 1999, 1,323 patients were accrued. Patients were randomly assigned to WP + NCHT, PO + NCHT, WP + AHT, or PO + AHT. Failure for PFS was defined as the first occurrence of local, regional, or distant disease; PSA failure; or death for any cause. Results: With a median follow-up of 59.5 months, WP RT was associated with a 4-year PFS of 54% compared with 47% in patients treated with PO RT (P = .022). Patients treated with NCHT experienced a 4-year PFS of 52% versus 49% for AHT (P = .56). When comparing all four arms, there was a progression-free difference among WP RT + NCHT, PO RT + NCHT, WP RT + AHT, and PO RT + AHT (60% v 44% v 49% v 50%, respectively; P = .008). No survival advantage has yet been seen. Conclusion: WP RT + NCHT improves PFS compared with PO RT and NCHT or PO RT and AHT, and compared with WP RT + AHT in patients with a risk of LN involvement of 15%.
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Authors: Kager Leo , Zoubek Andreas , Pötschger Ulrike , Kastner Ulrike , Flege Silke , Kempf-Bielack Beate , Branscheid Detlev , Kotz Rainer , Salzer-Kuntschik Mechthild , Winkelmann Winfried , Jundt Gernot , Kabisch Hartmut , Reichardt Peter , Jürgens Heribert , Gadner Helmut , Bielack Stefan S. 
Published: May 2003

Purpose: To determine demographic data and define prognostic factors for long-term outcome in patients presenting with high-grade osteosarcoma of bone with clinically detectable metastases at initial presentation. Patients and Methods: Of 1,765 patients with newly diagnosed, previously untreated high-grade osteosarcomas of bone registered in the neoadjuvant Cooperative Osteosarcoma Study Group studies before 1999, 202 patients (11.4%) had proven metastases at diagnosis and therefore were enrolled onto an analysis of demographic-, tumor-, and treatment-related variables, response, and survival. The intended therapeutic strategy included pre- and postoperative multiagent chemotherapy as well as aggressive surgery of all resectable lesions. Results: With a median follow-up of 1.9 years (5.5 years for survivors), 60 patients were alive, 37 of whom were in continuously complete surgical remission. Actuarial overall survival rates at 5 and 10 (same value for 15) years were 29% (SE = 3%) and 24% (SE = 4%), respectively. In univariate analysis, survival was significantly correlated with patient age, site of the primary tumor, number and location of metastases, number of involved organ systems, histologic response of the primary tumor to preoperative chemotherapy, and completeness and time point of surgical resection of all tumor sites. However, after multivariate Cox regression analysis, only multiple metastases at diagnosis (relative hazard rate [RHR] = 2.3) and macroscopically incomplete surgical resection (RHR = 2.4) remained significantly associated with inferior outcomes. Conclusion: The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma.
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Authors: Lipton A. , Ali S.M. , Leitzel K. , Demers L. , Harvey H.A. , Chaudri-Ross H.A. , Brady C. , Wyld P. , Carney W. 
Published: May 2003

Purpose: To determine the effect of elevated serum HER-2/neu on the response of metastatic breast cancer patients to an aromatase inhibitor versus an antiestrogen. Patients and Methods: Five hundred sixty-two estrogen receptor–positive metastatic breast cancer patients were randomized to first-line hormone therapy with either letrozole or tamoxifen. An automated enzyme-linked immunosorbent assay was used to detect serum HER-2/neu. Results: For patients with normal serum HER-2/neu (70.5%), objective response rate (ORR; 39% in letrozole-treated patients v 26% in tamoxifen-treated patients; P = .008), clinical benefit (CB; 57% v 45%; P = .016), time to progression (TTP; median, 12.2 v 8.5 months; P = .0019), and time to treatment failure (TTF; median, 11.6 v 6.2 months; P = .0066) were significantly better in patients treated with letrozole. In the elevated HER-2/neu group (29.5%), there was no significant difference in ORR (17% in letrozole-treated patients v 13% in tamoxifen-treated patients; P = .45) or CB (33% v 26%; P = .31), but there was a strong trend in favor of a longer TTP with letrozole (median, 6.1 v 3.3 months; P = .0596) and a significantly longer TTF with letrozole (median, 6.0 v 3.2 months; P = .0418). Multivariate analysis revealed that elevated serum HER-2/neu was a negative predictor for ORR and TTP. Conclusion: Patients with normal serum HER-2/neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen. Although in patients with elevated serum HER-2/neu there was no significant difference between letrozole and tamoxifen in ORR or CB, there was a strong trend favoring longer TTP and significantly longer TTF with letrozole.
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases
Authors: Bardou Valerie-Jeanne , Arpino Grazia , Elledge Richard M. , Osborne C. Kent , Clark Gary M. 
Published: May 2003

Purpose: To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer. Patients and Methods: Clinical outcomes of patients in two large databases were analyzed as a function of steroid receptor status. The first database (PP), contained 3,739 patients who did not receive any systemic adjuvant therapy and 1,688 patients who received adjuvant endocrine therapy but no chemotherapy. The second database (SPORE), contained 10,444 patients who received adjuvant endocrine therapy but no chemotherapy. Biochemical ER and PgR assays were identically performed in two different central laboratories. Results: In univariate and multivariate analyses, the prognostic significance of PgR status among systemically untreated patients is modest. Among endocrine-treated patients, however, multivariate analyses, including lymph-node involvement, tumor size, and age, demonstrate that PgR status is independently associated with disease-free and overall survival. For recurrence, the reduction in relative risk (RR) was 25% for ER-positive/PgR-negative patients and 53% for ER-positive/PgR-positive patients, compared with ER-negative/PgR-negative patients (P < .0001, PP patients). Patients with ER-positive/PgR-negative tumors have a reduction in RR of death of 30% (SPORE patients) and 38% (PP patients), compared with patients with ER-negative/PgR-negative tumors (P < .0001). For ER-positive/PgR-positive tumors, the reduction of the risk of death was greater than 46% in SPORE patients and 58% in PP patients, indicating that ER-positive/PgR-positive patients derive more benefit from endocrine therapy (P < .0001). Conclusion: When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy. Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients.
Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin
Authors: Rodriguez-Galindo Carlos , Wilson Matthew W. , Haik Barrett G. , Merchant Thomas E. , Billups Catherine A. , Shah Nirali , Cain Alvida , Langston James , Lipson Mindy , Kun Larry E. , Pratt Charles B. 
Published: May 2003

Purpose: To evaluate the efficacy of chemoreduction using vincristine and carboplatin in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in patients with intraocular retinoblastoma.Patients and Methods: Twenty-five patients (43 eyes) with newly diagnosed intraocular retinoblastoma received primary treatment with eight courses of vincristine and carboplatin. Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation.Results: Disease in all eyes responded to chemotherapy and progressed in only two patients before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% ± 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% ± 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those patients receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months).Conclusion: In combination with appropriate early intensive focal treatments, chemoreduction with vincristine and carboplatin, without etoposide, may be an alternative treatment for patients with early-stage intraocular retinoblastoma, although additional studies are needed. Patients with advanced intraocular disease require more aggressive treatments.
Role of phlebotomy in the management of hemoglobin SC disease: Case report and review of the literature
Authors: Markham Merry Jennifer , Lottenberg Richard , Zumberg Marc 
Published: May 2003

AbstractMarked variability is a keynote in the disease course of patients with hemoglobin SC (Hb SC) and hemoglobin S/β+‐thalassemia (Hb S/β+‐thal), with some patients having a frequency of complications and painful episodes similar to patients with homozygous sickle cell (Hb SS) disease. One possible explanation is that the higher hematocrit in these syndromes may contribute to an increase in blood viscosity, leading to vaso‐occlusive pain episodes as well as an increased incidence of thromboembolic complications and retinopathy. We present a patient with Hb SC disease with an excellent baseline functional status who developed splenic infarction at a high altitude. Following splenectomy, the patient developed a sustained increase in hematocrit, an increase in the frequency of painful episodes, as well as new‐onset dizziness and malaise. We initiated a therapeutic phlebotomy program in order to lower the hematocrit to pre‐splenectomy values, as well as to induce iron deficiency. Repeated phlebotomy resulted in a dramatic decrease in symptoms. Our patient no longer requires narcotic analgesics for pain, has resolution of constitutional symptoms, and has not required further hospitalizations for vaso‐occlusive pain crises. The correlation between symptoms and hematocrit levels supports the importance of blood viscosity in contributing to this patient's symptoms. A trial of phlebotomy to reduce viscosity in patients with higher hematocrit values should be considered as an intervention for symptomatic patients with sickle cell disease. Am. J. Hematol. 73:121–125, 2003. © 2003 Wiley‐Liss, Inc.
Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: A case report
Authors: Hayes‐Lattin Brandon , Blanke Charles D. , Deloughery Thomas G. 
Published: May 2003

AbstractExtramedullary plasmacytoma of the lung or brain parenchyma is rare. We report herein a case of extramedullary plasmacytoma involving both the lung and parenchymal brain. We review the literature, comparing and contrasting the current case. Am. J. Hematol. 73:131–134, 2003. © 2003 Wiley‐Liss, Inc.
Coenzyme Q10 levels in Prader‐Willi syndrome: Comparison with obese and non‐obese subjects
Authors: Butler Merlin G. , Dasouki Majed , Bittel Doug , Hunter Susan , Naini Ali , DiMauro Salvatore 
Published: May 2003

AbstractCoenzyme Q10 (CoQ10) is an essential component of the mitochondrial respiratory chain and an important scavenger of reactive oxygen species. Low levels are found in individuals with reduced energy expenditure, cardiac and skeletal muscle dysfunction, and mitochondrial disorders, many of these manifestations are seen in individuals with Prader‐Willi syndrome (PWS). In addition, CoQ10 supplementation frequently is given to individuals with this syndrome. To determine if CoQ10 levels are decreased in PWS, we studied plasma CoQ10 levels in 16 subjects with PWS, 13 with obesity of unknown cause, and 15 subjects without obesity but of similar age and compared with body composition. Plasma CoQ10 levels were significantly decreased (P < 0.05), using several statistical approaches in subjects with PWS (0.45 ± 0.16 μg/ml), compared to subjects without obesity (0.93 ± 0.56 μg/ml), but not different from subjects with obesity (0.73 ± 0.53 μg/ml). When plasma CoQ10 was normalized relative to cholesterol, triglyceride, and creatinine levels and fat and lean mass [determined by dual energy X‐ray absorptiometry (DEXA)] in the subjects with either PWS or obesity, no significant differences were observed. However, a lower muscle mass was found in the PWS subjects. © 2003 Wiley‐Liss, Inc.
Genetic and clinical characterization of patients with an interstitial duplication 15q11‐q13, emphasizing behavioral phenotype and response to treatment
Authors: Thomas J.A. , Johnson J. , Peterson Kraai T.L. , Wilson R. , Tartaglia N. , LeRoux J. , Beischel L. , McGavran L. , Hagerman R.J. 
Published: May 2003

AbstractThe clinical significance of an interstitial duplication of (15)(q11‐q13) remains unclear and controversial. The reported phenotypes vary widely and appear to be influenced by the parent of origin of the duplication. Aside from cases of dup(15) reported with autism, the behavioral phenotype of individuals with dup(15) has not been described. We present three families, two with intrachromosomal duplication (15)(q11‐q13) ascertained because of developmental delay in a relative. Two families show clear evidence of multigenerational maternal inheritance. The individuals discussed in this paper have minor anomalies and developmental delays. In addition, we describe a behavioral phenotype which often includes attention deficit hyperactivity disorder (ADHD) and autistic spectrum disorder. Responses to medications used to manage these behaviors are also described, including a positive response to methylphenidate and a poor response to fluoxetine. The duplication in each presenting individual, and available family members, was investigated utilizing cytogenetic and molecular techniques including high resolution cytogenetics, fluorescence in situ hybridization (FISH), DNA methylation studies, and quantitative fluorescence PCR. High resolution cytogenetic techniques alone missed some cases, demonstrating the need to confirm results with other methods. © 2003 Wiley‐Liss, Inc.
New syndrome of simplified gyral pattern, micromelia, dysmorphic features and early death
Authors: Basel‐Vanagaite Lina , Marcus Nufar , Klinger Gil , Shohat Mordechai , Levit Orly , Karmazin Boaz , Taub Ellen , Sirota Lea 
Published: May 2003

AbstractWe report two sisters with a new syndrome of simplified gyral pattern, normal head circumference at birth but with subsequent development of microcephaly, intractable seizures, and early death. Dysmorphic features included coarse face, hypertrichosis, short nose, paranasal widening, long philtrum, short neck, upper limb micromelia, single transverse palmar lines, and clasp thumbs. The proband had repeated convulsions from shortly after birth and she required continuous artificial ventilation. Neurological examination showed absent sucking, rooting, Moro and grasping reflexes. MRI revealed a diffuse simplified gyral pattern with apparent agyria over the frontal lobes. Biochemical screening gave normal results. Her older sister had bilateral renal pelvic dilatation on prenatal ultrasound. She also developed severe convulsions on the first day of life, and she had to be artificially ventilated for 38 days. She had severe developmental retardation and neurological examination showed absence of spontaneous movements and Moro reflex, weak sucking reflex, and hypertonicity. CT scan of the brain showed a simplified gyral pattern. At 3 months, she developed hypocalcemia and hyperphosphatemia with normal levels of vitamin D and alkaline phosphatase, and parathyroid hormone level was low. Other biochemical tests gave normal results. She died at 5 months due to a massive aspiration event. Based on the unique clinical and radiological features found in our patients, we propose that this is a new syndrome. © 2003 Wiley‐Liss, Inc.
Mortality and apolipoprotein E in African‐American, and White Elders: An attempted replication
Authors: Fillenbaum Gerda G. , Burchett Bruce M. , Lee Joseph H. , Blazer Dan G. 
Published: May 2003

AbstractWe have tried, with only partial success, to confirm findings in a recently reported study in this journal on the relationship of APOE genotype to mortality in community representative Hispanics (n = 659), Whites (n = 272), and African‐Americans (n = 450), aged 65 and over, living in Northern Manhattan, New York. That study found that using proportional hazards models adjusted for sex and lipid levels, Hispanics and Whites with the E2/E3 genotype, but not African‐Americans, had the lowest mortality risk. Those under age 75 had risks comparable to those over age 75, suggesting minimal survivor bias. Nearly 50% of the mortality risk associated with the APOE genotype appeared to act through heart disease, diabetes, and stroke. The current study of African‐Americans (n = 1,083) and Whites (n = 915) aged 71 and over living in the more rural Southeastern US, found no protective effect of the E2/E3 genotype for either African‐Americans or Whites. Among younger Whites (age 71–75), point estimates suggested that the E2/E3 genotype might be protective, but at a nonsignificant level; self‐reported African‐American race, but not genotype, was a risk factor for mortality in this age group. Neither lipid level nor health condition attenuated the effect of APOE genotype. Differences in findings may reflect issues of sampling, age, the relative distribution of the APOE alleles, or some other factor. Until such time as studies use truly representative samples and include younger ages, findings in this area must be treated with caution. © 2003 Wiley‐Liss, Inc.
Cage opening of 1,2‐(CH2OH)2‐closo‐1,2‐C2B10H10 with 2‐(aminomethyl)‐pyridine: synthesis and structure of a cobalt salt of functionalized nido‐C2B9H10 mono anion
Authors: Oki Aderemi R. , Gilbes Blanca , Tarasyuk Faina , Emge Thomas J. 
Published: May 2003

AbstractThe reaction of 1,2‐(CH2OH)2‐closo‐1,2‐C2B10 H10 carborane with 2‐(aminomethyl)‐pyridine in methylene chloride at room temperature led to the partial cage degradation of the closo carborane and its conversion to the nido derivative. The addition of cobalt chloride hexahydrate in methanol to the mixture produced orange crystals 1. The crystal structure of the orange compound has been determined. Copyright © 2003 John Wiley & Sons, Ltd.
Synthesis and structures of [Yb {η5‐(C5H4)B(NiPr2)NHtBu} 2 {N(SiMe3)2} ] and [Zr {η5‐(C9H6)B(N(SiMe3)2)(C9H7)} Cl2]
Authors: Braunschweig Holger , Kraft Mario , Homberger Melanie , Breitling Frank M. , White Andrew J. P. , Englert Ulli , Williams David J. 
Published: May 2003

AbstractBoth amido‐(cyclopentadienyl)boranes and bis(cyclopentadienyl)boranes of the types R2NB(CxHy) (NR′) and R2NB(CxHy)2 (R = alkyl, trimethylsilyl; R′ = Ph; CxHy = C5H5 (cyclopentadienyl), C9H7 (indenyl), C13H9 (fluorenyl)) were recently shown to form corresponding boron‐bridged Group 4 metallocenes that exhibit high activities in Ziegler–Natta‐type catalysed olefin polymerization. Here, the same boranes were utilized in the formation of metallocenes of ytterbium and zirconium, where the ligands selectively bind in a non‐chelate fashion. The resulting complexes [Yb { η5‐(C5H4)B(NiPr2)NHtBu} 2 {N(SiMe3)2} ] (2) and [Zr {η5‐(C9H6)B(N(SiMe3)2)(C9H7)} Cl2] (4) allow studies on these ligands in a metal‐bonded, though unstrained, environment. Furthermore, these complexes might find use as precursors in the formation of organometallic polymers, since they exhibit a readily available moiety for the coordination of further transition metal centres. Both complexes were fully characterized by multinuclear magnetic resonance spectroscopy and X‐ray structure determination. Copyright © 2003 John Wiley & Sons, Ltd.